Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF DILUTIVE COMMON STOCK EQUIVALENTS (Details)

v3.22.1
SCHEDULE OF DILUTIVE COMMON STOCK EQUIVALENTS (Details) - shares
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 3,459,793 96,506
Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total [1] 87,697
Stock Options [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 929,701 7,809
Stock Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 2,530,092 1,000
[1] 87,697 shares of our common stock issuable upon conversion of $1,186,176 of Convertible Notes Payable as of March 31, 2021 not accounting for 4.99% beneficial ownership limitations.